Logo
x

Search category

Subscribe Now

EULAR 2021

PharmaShots Interview: Eli Lilly's Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

PharmaShots Interview: Eli Lilly's Dr. Lotus Mallbris Shares Insight on the Data of Taltz and Olumiant Presented at EULAR 2021

  • August 2, 2021
Celltrion Presents One Year Results of Yuflyma (biosimilar- adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULAR 2021

Celltrion Presents One Year Results of Yuflyma (biosimilar- adalimumab) in P-III CT-P17 3.1 Trial for Rheumatoid Arthritis at EULA...

  • June 3, 2021
AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULAR 2021

AstraZeneca Presents Results of Anifrolumab in New Post-Hoc Analysis of P-III TULIP Study for Systemic Lupus Erythematosus at EULA...

  • June 2, 2021
Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

Novartis Presents Two-Year Data of Cosentyx in P-III JUNIPERA Study for JPsA and ERA at EULAR 2021

  • June 2, 2021
AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheumatoid Arthritis at EULAR 2021

AbbVie Presents Results of Long-Term Efficacy and Safety Analyses for Rinvoq (upadacitinib) in P-III SELECT-COMPARE Study for Rheu...

  • June 2, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.